Brazil Medical Education And Digital Trends Will Secure Future Opportunity

Key Takeaways

• Expanding medical education offerings and digital initiatives are strengthening revenue growth, operating leverage, and profitability through increased student intake and higher-margin recurring revenues.
  
• Operational efficiencies and disciplined acquisitions are enhancing margin expansion, earnings stability, and long-term market share in the Brazilian medical education sector.
  
• Intensified competition, tax changes, digital engagement declines, and revenue concentration in medical education heighten risks to Afya's future growth, margins, and earnings stability.

Catalysts

Operates as a medical education group in Brazil.

• The company expects continued strong demand for medical education in Brazil, fueled by the country's persistent shortage of physicians, expanding aging population, and greater healthcare access-supporting both rising student intake and stable/rebounding tuition pricing, which drives higher revenues over time.
  
• Afya's recent expansion of approved medical seats (via the FUNIC acquisition and ramp-up of new campuses), as well as ongoing strong undergrad enrollment growth (up 14% YOY), demonstrates its ability to capitalize on high demand, leading to top-line growth and improving operating leverage, benefiting EBITDA margins and profitability.
  
• Digital initiatives and cross-segment integration-including Medical Practice Solutions and Continuing Education-are increasing recurring, higher-margin digital revenues and operational synergies, which should lead to sustained net margin expansion and greater earnings stability.
  
• The company's focus on operational efficiencies (including centralized shared services and cost controls across all segments) is expected to continue driving SG&A expense dilution and margin expansion, enhancing future net income and free cash flow.
  
• M&A opportunities in Brazil's medical education market are becoming more attractive due to pressured sellers, and Afya remains well-positioned and financially disciplined to execute value-accretive acquisitions, further increasing market share, student base, and long-term revenue potential.

Afya Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

• Analysts are assuming Afya's revenue will grow by 7.3% annually over the next 3 years.
• Analysts assume that profit margins will increase from 20.1% today to 21.5% in 3 years time.
• Analysts expect earnings to reach R$1.0 billion (and earnings per share of R$10.55) by about June 2029, up from R$757.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting R$1.1 billion in earnings, and the most bearish expecting R$822.1 million.
• In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 9.8x on those 2029 earnings, up from 8.6x today. This future PE is lower than the current PE for the US Consumer Services industry at 16.1x.
• Analysts expect the number of shares outstanding to decline by 1.98% per year for the next 3 years.
• To value all of this in today's terms, we will use a discount rate of 10.46%, as per the Simply Wall St company report.

Risks

• Heightened competition due to recent increases in approved medical seats and institutions in Brazil has led to a reduction in the candidates-per-seat ratio (from 7 to 5), signaling intensified competition for student recruitments, which could pressure tuition pricing and limit future enrollment growth, negatively affecting long-term revenues.
  
• New tax legislation aligned with OECD Pillar Two introduces higher and less predictable effective tax rates (expected to rise from 9% to 15%), combined with uncertainty around the qualification of social programs like PROUNI for credits, which may reduce the company's net margins and overall net earnings.
  
• The Medical Practice Solutions segment's active monthly users declined 9% year-over-year, while the B2B component decreased 8%, indicating stagnation or shrinking engagement in digital health services, which could erode projected recurring revenues and hinder long-term EBITDA expansion.
  
• Over 94% of Afya's revenue is concentrated in health-related and especially medical programs, exposing the company to regulatory or market risks specific to the healthcare education sector and limiting diversification; any secular decline in demand for medical education in Brazil could create significant future earnings volatility.
  
• The Continuing Education segment saw a 29% year-over-year decline in the "residency journey," reflecting potential shifting industry dynamics, increased market competition, or changing demand for advanced medical qualifications, which may constrain segment recovery, limit top-line growth, and reduce future profitability.

Valuation

How have all the factors above been brought together to estimate a fair value?

• The analysts have a consensus price target of $17.25 for Afya based on their expectations of its future earnings growth, profit margins and other risk factors.
• However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $21.95, and the most bearish reporting a price target of just $15.18.
• In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be R$4.7 billion, earnings will come to R$1.0 billion, and it would be trading on a PE ratio of 9.8x, assuming you use a discount rate of 10.5%.
• Given the current share price of $14.5, the analyst price target of $17.25 is 16.0% higher.
• We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.